Watch Ticker

Indaptus Therapeutics, Inc. Common Stock

Go to Indaptus Therapeutics, Inc. Common Stock Website

$7.40

-0.30 (-3.90%)

Live

Previous Close

$7.7

Day Range

$7.3443 - $7.76

Previous Day Range

$7.1 - $7.8435

Market Cap

$4.2 million USD

Day Vol.

1791

Previous Day Vol.

5818

Currency

USD

Primary Exchange

Nasdaq

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

N/A - Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Indaptus Therapeutics, a clinical-stage biotechnology company, highlights its accomplishments in 2024 and outlines its strategic goals for 2025, including the launch of a combination trial with BeiGene's tislelizumab and the expansion of its Decoy20 clinical trial.

Related tickers: INDP, ONC.

Read Full Article

N/A - Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Indaptus Therapeutics presented positive interim safety data from a Phase 1 trial of its lead compound Decoy20, which showed an acceptable safety profile and signs of anti-tumor activity. The company plans to combine Decoy20 with a PD-1 inhibitor in a new cohort.

Related tickers: INDP, BGNE.

Read Full Article

Trending Tickers

Please sign in to view